PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 18, 2026Lung Cancer Targets and Therapy0 citationsOpen Access

Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients

View Full Paper
PLPutthapoom LumjiaktaseNKNanthisa KemawichanuratKSKanthon Santiwiwas

Key Points

  • This study aims to identify blood biomarkers that can predict chemotherapy response and survival outcomes in patients with non-targetable advanced NSCLC.
  • Blood samples were collected from 42 patients before and after chemotherapy.
  • Flow cytometry was used to analyze circulating immune cells and Treg subpopulations.
  • Multiplex bead-based assays quantified human immune checkpoint biomarker levels.
  • Higher pre-chemotherapy sCD25 levels were linked to worse progression-free survival.
  • Increased neutrophil to lymphocyte ratio correlated with shorter overall survival.
  • Improved clinical benefit rate was associated with higher pre-chemotherapy %NKT cells.

Abstract

Purpose: Chemotherapy is the main therapy for non-targetable advanced non-small cell lung cancer (NSCLC). Nevertheless, few biomarkers are currently available for predicting clinical outcomes and monitoring treatment response. Patients and Methods: The blood samples of 42 patients with non-targetable advanced NSCLC who received chemotherapy were collected before chemotherapy and after chemotherapy. The circulating immune cells and subpopulation Treg were investigated using flow cytometry, and human immune checkpoint biomarker levels were analysed by multiplex bead-based assay. Results: After selecting the effective biomarkers for survival analysis, high pre-chemotherapy sCD25 (≥ 499.52 pg/mL; 4.52 vs 14.98 months, p = 0.030) and post-chemotherapy (≥ 515.23 pg/mL; 3.90 vs 21.25 months, p = 0.004) were associated with poorer median progression-free survival (PFS). An increase in pre-chemotherapy neutrophil to lymphocyte ratio (NLR) (ratio ≥ 6.9; 5.15 vs 21.54 months, p = 0.008) and post-chemotherapy NLR (ratio ≥ 3.1; 10-month OS 50.35% vs 83.57%, p = 0.014) was correlated with shorter overall survival (OS). Moreover, increased pre-chemotherapy %NKT cells (≥ 6.8%) were linked to improved clinical benefit rate (CBR) (2.72 vs 3.97 months, p = 0.013), while higher post-chemotherapy %NK cells (≥ 23.1%) were associated with rapid overall response rate (ORR) at 4 months (82.05% vs 25%, p = 0.035). Conclusion: Our findings suggest that sCD25 and NLR show potential as indicators of PFS and OS, respectively. Additionally, pre-chemotherapy %NKT and post-chemotherapy %NK cells may provide insight into monitoring chemotherapy response. This pilot study identified potential candidate biomarkers for further investigation to confirm their clinical utility. Keywords: non-targetable advanced NSCLC, immunological biomarkers, chemotherapy, survival outcomes, clinical response

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lumjiaktase et al. (2026) studied this question.

synapsesocial.com/papers/69ba43a84e9516ffd37a5197https://doi.org/10.2147/lctt.s578622
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer2012 · 133 citations
  2. 2Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancer2025 · 4 citations
  3. 3Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-042015 · 262 citations
  4. 4Percentages of NKT cells in the tissues of patients with non-small cell lung cancer who underwent surgical treatment2014 · 3 citations
  5. 5Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives2022 · 114 citations